Anastrozole

CAS 120511-73-1

About the API

Molecular Formula C17H19N5
Molecular Weight 293.366 g/mol
Therapeutic category Oncology
Available formulations Oral Solid
Regulations Canada DMF Flag Canada DMF CEP Flag CEP EU DMF Flag EU DMF Japan DMF Flag Japan DMF Other Flag Other US DMF Flag US DMF

General Information

Teva api’s process development and production capabilities in synthetic organic chemistry cover a broad range of synthetic products and state-of-the-art technologies.

 

Our development expertise is backed by our comprehensive understanding of these processes and an unwavering commitment to R&D investment. As a result, we provide you with high-quality APIs at competitive prices, while meeting the most stringent industry standards.

 

Our capabilities in the field of synthetic organic chemistry include, among others: O-alkylation, N-alkylation, aliphatic and aromatic nucleophilic substitution, catalytic hydrogenation, catalytic reduction, biocatalysis, and oxidation (including asymmetric sulfoxidation).

Teva api provides a robust synthetic process from API conception all the way to commercial production. This process is specifically designed to be atom-efficient, safe and environmentally friendly without compromising product purity. The most rigid analytical and physical control methods are utilized to deliver desired polymorphs compatible with the stringent demands of regulatory bodies in target countries. And, our knowledgeable IP experts are available to answer questions and help you maintain your competitive edge in the marketplace.

 

Teva api’s operates seven R&D centers worldwide. There, our top researchers with wide-ranging scientific expertise continually strive to improve our processes so you benefit from industry-leading learnings and materials. Scientists in several of TAPI’s large pilot plants with capacities ranging from 200 ml to 480 l are developing technologies to deliver and implement new processes that will enhance our production capabilities.